Oxford Nanopore Technologies has delivered a 69.5% gain year to date, which puts a spotlight on a simple but important issue for anyone looking at the shares today. Is the current market value of the business in line with the cash it is expected to generate over time, or has sentiment moved ahead of the underlying numbers?
- A 69.5% move so far in 2026 puts recent enthusiasm for Oxford Nanopore Technologies to the test, because such a rise raises the bar for what its future cash flows need to justify.
- The new India Genomics Centre of Excellence, created with partners in the UK and India, may support expectations for future cash inflows by broadening the company’s footprint in applied genomics and potentially pulling some projects and collaborations forward.
- Prefer to judge Oxford Nanopore Technologies on sales? See what Oxford Nanopore Technologies's 9.0x P/S says about the price.
The issue now is whether the current share price of Oxford Nanopore Technologies is broadly aligned with what its Discounted Cash Flow (DCF) intrinsic value estimate suggests based on the business’s cash flows.
If you are weighing whether Oxford Nanopore Technologies' 69.5% year to date gain is justified by its cash flows, it can help to compare that question across 7 high quality undervalued stocks
Has Oxford Nanopore Technologies Run Too Far on Cash Flow?
The Discounted Cash Flow (DCF) model here asks what Oxford Nanopore Technologies' future cash generation could be worth today. Latest twelve month free cash flow sits at a loss of £117.8 million, and the projections used in this DCF assume that outflows gradually shrink before turning to positive cash generation later in the next decade.
Those assumptions build in a recovering, then growing, free cash flow profile, which needs to be weighed against the current share price of £2.17. The DCF outcome points to an estimated intrinsic value that is substantially below that price, so the present valuation already reflects a lot of optimism about Oxford Nanopore Technologies' future funding needs and eventual scale. The new India Genomics Centre of Excellence with partners in the UK and India gives Oxford Nanopore Technologies extra routes for research and collaboration, yet the DCF outcome suggests the market is pricing in more than these projected cash flows support. Find out what Oxford Nanopore Technologies could be worth using our Discounted Cash Flow (DCF) estimate.
The Oxford Nanopore Technologies Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Oxford Nanopore Technologies valuation question leaves off. They map out the future paths for growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today’s price. They then tie each scenario to its own view of fair value based on specific potential catalysts and risks so you can watch over time which storyline appears to be taking shape on the Community page.
A clear written Narrative on Oxford Nanopore Technologies forces every assumption about future cash flows, valuation and funding needs onto the page so you can see exactly what needs to happen for today’s share price to make sense. With projects such as the India Genomics Centre of Excellence now in play, a number-driven story gives you a concrete way to track whether that kind of development is feeding into the business outcomes that Oxford Nanopore Technologies' current valuation appears to imply.
Share your own Narrative for Oxford Nanopore Technologies and set out the assumptions behind your valuation.
Before you stop at price, one more Oxford Nanopore Technologies check matters
Oxford Nanopore Technologies also trips specific risk checks in Simply Wall St’s broader review, and those red flags can change how you read every cash flow assumption and funding line you have just seen. Take a closer look at 2 warning signs before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com